Ambrx Biopharma Inc - ADR

NYSE:AMAM   3:59:51 PM EDT
4.98
-0.05 (-0.99%)
Products, Regulatory

Ambrx Biopharma Inc Presents Positive Data From Ongoing Ace-Breast-01 Phase 1 Clinical Study Of ARX788 At San Antonio Breast Cancer Symposium

Published: 12/09/2021 14:10 GMT
Ambrx Biopharma Inc - ADR (AMAM) - Ambrx Biopharma Inc. Presents Positive Data From Ongoing Ace-breast-01 Phase 1 Clinical Study of Arx788 at San Antonio Breast Cancer Symposium.
Ambrx Biopharma Inc - Arx788 Demonstrated Robust Anti-tumor Activity, With Disease Control Rate of 100% in 29 Patients Treated at 1.5 Mg/kg Q3w.
Ambrx Biopharma Inc - Arx788 Demonstrated Treatment Effect Among Patients Who Previously Failed a Median of Seven Anti-her2 Targeting Therapies.